Holen Sie sich die Stockscreener-App
3.59
0.84%
0.03
Vorhandelsmarkt:
3.67
0.08
+2.23%
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
Editas Medicine: Three Strikes And It's Out, Or Third Time’s The Charm? - Seeking Alpha
Is Editas Medicine Inc. stock attractive after correctionMarket Performance Report & Reliable Breakout Forecasts - newser.com
Editas Medicine at H. C. Wainwright: Aiming for LDL-C Breakthrough By Investing.com - Investing.com Canada
Editas Medicine Inc. stock volume spike explainedJuly 2025 Short Interest & Weekly High Conviction Trade Ideas - newser.com
Using flow based indicators on Editas Medicine Inc.Trade Risk Summary & Technical Buy Zone Confirmations - newser.com
Editas Medicine Inc. stock momentum explainedM&A Rumor & AI Enhanced Market Trend Forecasts - newser.com
How high can Editas Medicine Inc. stock goWeekly Trend Report & Daily Profit Focused Stock Screening - newser.com
Can Editas Medicine Inc. stock sustain institutional interestJuly 2025 Setups & High Accuracy Investment Signals - newser.com
Why Editas Medicine Inc. stock is in analyst buy zoneQuarterly Investment Review & Low Risk Investment Opportunities - newser.com
Can Editas Medicine Inc. stock weather global recessionJuly 2025 Analyst Calls & Free Accurate Trade Setup Notifications - newser.com
Published on: 2025-10-13 07:58:32 - newser.com
Published on: 2025-10-12 10:38:16 - newser.com
What analysts say about Editas Medicine Inc stockShort Interest Overview & Grow Smarter With Pro-Level Research - earlytimes.in
Editas Medicine Hits New 52-Week High of $4.05, Marking Key Milestone - Markets Mojo
Editas Medicine Inc 8EM Stock Analysis and ForecastSwing Trading Ideas & Free High Return Strategy Alerts - earlytimes.in
How Editas Medicine Inc. (8EM) stock valuation compares with sectorGold Moves & Capital Efficiency Focused Strategies - newser.com
Leading vs lagging indicators on Editas Medicine Inc. performanceTrade Ideas & Technical Pattern Based Signals - newser.com
CRISPR Market Size, Share, Recent Developments, Growth - openPR.com
Regression analysis insights on Editas Medicine Inc. performanceQuarterly Earnings Report & High Conviction Buy Zone Alerts - newser.com
Is Editas Medicine Inc. (8EM) stock a top hedge fund pickBond Market & Low Drawdown Trading Strategies - newser.com
Editas Medicine (NASDAQ:EDIT) Receives Sell (E+) Rating from Weiss Ratings - MarketBeat
Editas Medicine Hits New 52-Week High at $4.07, Marking Significant Milestone - Markets Mojo
Editas Medicine Unveils Promising Preclinical Data on EDIT-401 - TipRanks
Editas Medicine Hits New 52-Week High of $4.54, Marking Significant Milestone - Markets Mojo
Editas Medicine reports 90% LDL-C reduction in preclinical studies By Investing.com - Investing.com Nigeria
Editas Medicine reports 90% LDL-C reduction in preclinical studies - Investing.com India
Editas Medicine (EDIT) Showcases Promising Preclinical Data for LDL Reduction - GuruFocus
Editas Medicine Reports Promising Preclinical Data for LDL-Cholesterol-Lowering Gene Editing Therapy EDIT-401 at ESGCT Congress - Quiver Quantitative
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress - The Manila Times
Editas Medicine Reports In Vivo Proof-of-Concept Data for - GlobeNewswire
Editas Medicine reports 90% LDL cholesterol reduction in animal studies - StreetInsider
Editas Medicine Inc. stock retracement – recovery analysis2025 Trade Ideas & Weekly Top Performers Watchlists - newser.com
Best data tools to analyze Editas Medicine Inc. stockForecast Cut & Fast Entry High Yield Tips - newser.com
Historical volatility pattern of Editas Medicine Inc. visualizedFed Meeting & Target Return Focused Stock Picks - newser.com
How risky is Editas Medicine Inc. stock nowWeekly Investment Recap & Weekly Top Stock Performers List - newser.com
While institutions invested in Editas Medicine, Inc. (NASDAQ:EDIT) benefited from last week's 11% gain, individual investors stood to gain the most - Sahm
Editas Medicine to present CRISPR cholesterol research at ESGCT By Investing.com - Investing.com Nigeria
Editas Medicine to present CRISPR cholesterol research at ESGCT - Investing.com
Editas Medicine to Present Groundbreaking LDL-Cholesterol-Lowering CRISPR Gene Editing Research at ESGCT Congress 2025 - Quiver Quantitative
Editas Medicine Announces EDIT-401 Oral Presentation at the - GlobeNewswire
Editas Medicine to present EDIT-401 data at gene therapy congress - StreetInsider
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences - Yahoo Finance
How Editas Medicine Inc. (8EM) stock responds to job market shiftsEarnings Growth Report & Reliable Volume Spike Trade Alerts - newser.com
Real time alert setup for Editas Medicine Inc. performanceJuly 2025 Earnings & Capital Efficiency Focused Ideas - newser.com
Will Editas Medicine Inc. continue its uptrendForecast Cut & Expert Curated Trade Ideas - newser.com
Using data filters to optimize entry into Editas Medicine Inc.Trade Volume Summary & Precise Buy Zone Identification - newser.com
Is Editas Medicine Inc. (8EM) stock vulnerable to rate hikesEarnings Performance Report & Weekly Sector Rotation Insights - newser.com
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):